December 22, 2020
In The News
Read Article
Tag Archives: Atomwise Partnerships
December 21, 2020
In The News
After raising $123 million this past summer to fuel its artificial-intelligence-based drug design work, Atomwise has helped launch a new company focused on uncovering treatments in immuno-oncology.
December 18, 2020
In The News
A2i Therapeutics secures seed funding from FutuRx and its investors – Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority – to develop novel small molecule immuno-oncology agents.
July 31, 2019
In The News
Mel Yeates from DDNews reports on some of Atomwise’s recent partnerships with Eli Lilly and Enamine.